Tilray Brands, Inc.

TLRY

278
📌 TLRY: Why did the stock soar 65% and what's next?

Last week saw the biggest weekly gain in the company's history.

We won't go into too much detail on the fundamentals, but here's a quick overview:

Revenue breakdown by product for the quarter:

Canadian recreational cannabis: ~$59.1 million — the core of the Canadian business

Canadian medical cannabis: ~$6.7 million

International medical cannabis: ~$14.9 million — the key growth rate (+71% in the last quarter of 2025!)

At the same time, cash flows, and earnings are in negative territory on a TTM basis.

Net debt ~59 M

P/B ~0.9

Now to the most interesting part:

This share price increase is related to the likelihood of cannabis being reclassified in the US from Schedule I to Schedule III of controlled substances.

What does this mean:

1. Repeal of Section 280E of the US Internal Revenue Code

Currently, companies operating with cannabis in the US cannot deduct regular business expenses (rent, salaries, marketing) when calculating their income taxes. This severely compresses margins.

Reclassification will automatically remove this limitation.

2. Access to Capital and Banks

คำจำกัดสิทธิ์ความรับผิดชอบ

ข้อมูลและบทความไม่ได้มีวัตถุประสงค์เพื่อก่อให้เกิดกิจกรรมทางการเงิน, การลงทุน, การซื้อขาย, ข้อเสนอแนะ หรือคำแนะนำประเภทอื่น ๆ ที่ให้หรือรับรองโดย TradingView อ่านเพิ่มเติมใน ข้อกำหนดการใช้งาน